Nation
World
Politics
Sports
Business
Entertainment
Life
Tech
Science
Opinion
Crime
Health
Oddities

Alphabet and Pfizer Stock Look Like Buys, Says This Longtime Market Maven

Por: MarketWatch Business November 26, 2022

thumbnail

Rosenberg has been interviewed many times by Barron’s and has made some prescient calls. In late 2011, he compared (MSFT) favorably to (IBM), which had then drawn a big investment from (BRK.A). “Warren Buffett came pretty late to the IBM party,” he said. Microsoft is up tenfold since then, while IBM stock is in the red. Buffett subsequently gave up on Big Blue and sold Berkshire’s stake. Rosenberg follows the markets closely and now is... + full article



Similar News

Alphabet and Pfizer Stock Look Like Buys, Says This Longtime Market Maven

MarketWatch USA Business November 26, 2022

thumbnailRosenberg has been interviewed many times by Barron’s and has made some prescient calls. In late 2011, he compared (MSFT) favorably to (IBM), which had then drawn a big investment from (BRK.A). “Warren Buffett came pretty late to the IBM party,” he said. Microsoft is up... + más

Alphabet and Pfizer Stock Look Like Buys, Says This Longtime Market Maven | MarketWatch

Pfizer CEO reveals 2030 growth plan as company faces up to $18 billion revenue hit from generics | CNBC


Billionaire Hedge Fund Investor Urges Alphabet To Cut Costs: ‘No Justification’ For Salaries That Are ‘Too High’

Forbes USA Business November 15, 2022

thumbnailUpdated Nov 15, 2022, 02:29pm ESTTopline TCI Fund Management, the activist hedge fund helmed by U.K. billionaire Christopher Hohn, touted a massive stake in Google parent Alphabet on Tuesday as he called on the company to cut costs by reducing its head count and paying workers... + más

Billionaire hedge fund founders are readying their firms to outlast them. Here's the next generation of leaders as industry titans like Ray Dalio step back. | Business Insider

Activist investor TCI calls on Google parent Alphabet to slash costs | Fox Business


Pfizer CEO reveals 2030 growth plan as company faces up to $18 billion revenue hit from generics

CNBC USA Health November 02, 2022

thumbnailPfizer CEO Albert Bourla talks during a press conference with European Commission President after a visit to oversee the production of the Pfizer-BioNtech Covid-19 vaccine at the factory of US pharmaceutical company Pfizer, in Puurs, on April 23, 2021.John Thys AFP Getty Images... + más

Pfizer raises 2022 earnings guidance, beats third-quarter expectations | CNBC

Pfizer climbs on strong Q3 results, raised outlook | MarketWatch


Pfizer rides Paxlovid sales to better-than-expected quarter

ABC News USA Business November 01, 2022

thumbnailPfizer’s COVID-19 treatment helped the pharmaceutical giant balance tumbling international sales for its vaccine and top third-quarter expectations.The pill treatment Paxlovid brought in $7.5 billion in sales in the quarter and has generated more than $17 billion so far this... + más

Covid-19 treatment Paxlovid can interact with common heart medications, doctors warn | CNN

Pfizer raises 2022 earnings guidance, beats third-quarter expectations | CNBC


Pfizer raises 2022 earnings guidance, beats third-quarter expectations

CNBC USA Health November 01, 2022

thumbnailIn this articleVials containing the Pfizer/BioNtech vaccine against the coronavirus disease (COVID-19) are displayed before being used at a mobile vaccine clinic, in Valparaiso, Chile, January 3, 2022.Rodrigo Garrido Reuters on Tuesday raised its 2022 earnings guidance after... + más

Pfizer CEO reveals 2030 growth plan as company faces up to $18 billion revenue hit from generics | CNBC

Pfizer climbs on strong Q3 results, raised outlook | MarketWatch


Pfizer says it's eyeing a $110 to $130 list price for COVID-19 vaccine in U.S.

Fox Business USA Business October 22, 2022

thumbnailFox News contributor Dr. Janette Nesheiwat discusses Pfizer’s new anti-viral COVID-19 pill and the importance of early treatment. has revealed the price it is eyeing in the U.S. for its adult COVID-19 vaccine on the commercial market. Ticker Security Last Change Change %... + más

Moderna sues Pfizer over patents behind COVID-19 vaccine | The Advocate

Pfizer says COVID-19 vaccine will cost $110-$130 per dose | ABC News


Moderna sues Pfizer over patents behind COVID-19 vaccine

The Advocate USA Crime October 10, 2022

thumbnailvaccine maker Moderna is suing Pfizer and the German drugmaker BioNTech, accusing its main competitors of copying Moderna’s technology in order to make their own vaccine.Moderna said Friday that Pfizer and BioNTech’s vaccine Comirnaty infringes on patents Moderna filed... + más

Moderna is suing Pfizer over its coronavirus vaccine | The Verge

Moderna vs Pfizer: Is it OK to mix and match the updated COVID-19 booster shots? | Los Angeles Times



About iurex | Privacy Policy | Disclaimer |